Moderate Renal Impairment Clinical Trial
An Open-Label Clinical Study to Evaluate the Pharmacokinetics of MK-0616 Following Administration of a Single Dose to Participants With Moderate Renal Impairment
This purpose of this study is to compare the pharmacokinetics (PK) of a single dose of MK-0616 in participants with moderate renal impairment (RI) to those of healthy matched control participants. This study is being conducted to assess the impact of moderate renal insufficiency on the PK of MK-0616.
|Source||Merck Sharp & Dohme Corp.|
|Status||Not yet recruiting|
|Start date||October 25, 2021|
|Completion date||May 24, 2022|